An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019. The spray was previously approved as a companion treatment to an oral antidepressant, as well as a ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...